BioNTech's CEO Handoff and Guided Reset: Oncology Takes the Wheel as COVID Fades

New leadership, a steepened 2026 guidance cut, and a data-rich pipeline mark BioNTech's turn from pandemic winner to multiproduct oncology contender.

BNTX · Earnings Call · 2026-08-04

A Leadership Shuffle with Strategic Purpose

On BioNTech's second-quarter earnings call, the headline was not a molecule but a departure. Supervisory Board Chairman Helmut Jeggle announced that Guido Oelkers, former CEO of Sobi, will take over as CEO no later than February 1, replacing co-founder Ugur Sahin. Jeggle framed the move as a natural evolution: “Guido is an excellent fit on all 3 dimensions” — Helmut Jeggle, Member of Management Board · 2026-08-04—strategic leadership, scaling a global biopharma, and building innovation-driven organizations. Ugur echoed this, describing the transition as the company's passage from “a pioneering research organization into a global biopharmaceutical company with multiple commercial products.” The keyword Guido spikes this quarter as a company-unique mover, confirming this is a fresh theme, not incremental chatter. Notably, this pivot to a commercial-scale CEO follows months of speculation about the founders' next act. In the March 2026 call, Ugur teased a new venture centered on next-generation mRNA and AI. “You can imagine, Daina is – and you are very close to that, that the field in the mRNA space is rapidly advancing,” — Ugur Sahin, Co-Founder, CEO · 2026-03-10 he said. Now the founders are exiting, and the new CEO is expected to industrialize a late-stage oncology pipeline that has already started to deliver.

Guidance Cut: The COVID Dividend Has Faded

The financial reset was harsher than expected. CFO Ramón Zapata-Gomez trimmed full-year 2026 revenue guidance from the prior €2.2–€2.5 billion range down to €1.6–€1.9 billion. Second-quarter revenue fell 60% year-over-year to €106 million, driven by lower U.S. COVID vaccine demand and a prior-year onetime compensation payment from Pfizer. In Q&A, Zapata quantified the driver: “80% is COVID-related completely and then the rest is the loss of the out-license milestones.” — Ramón Zapata-Gomez, Chief Financial Officer · 2026-08-04 Germany, a direct market, will use last year's stockpile, compounding the pain. Yet the balance sheet remains a fortress – €16.6 billion in cash and securities, up from €16 billion in mid-2025. The company is using that cushion to fund a more focused pipeline. Adjusted R&D dropped 6% Y/Y to €477 million, and SG&A climbed 45% to €198 million as BioNTech builds commercial infrastructure. The revised guidance reflects interim analysis timing, not a retreat from science. Ramon framed it as deliberate: “These charges reflect our progression from announcing the acquisition to actively executing it.” — Ramón Zapata-Gomez, Chief Financial Officer · 2026-08-04

Pipeline Momentum: Pumitamig, ADCs, and a Watchful Eye on Readouts

The science story is as strong as the COVID story is weak. Pumitamig, the PD-L1/VEGF bispecific partnered with BMS, is now in four registrational programs across lung cancer. Ozlem highlighted that global Phase II data in first-line non-small cell lung cancer showed a confirmed overall response rate of 62.5% across PD-L1 expression levels, with disease control appearing durable. She stressed cross-regional consistency with China trials, a critical validation for investors skeptical of Chinese data. Beyond Pumitamig, the B7-H3 ADC (elfetabart, previously BNT324) is advancing into a Phase III trial in metastatic castration-resistant prostate cancer – a new setting with high unmet need. Ugur explained the rationale: “What is very encouraging for our B7-H3 is the combination of durable disease control plus the so far excellent safety profile.” — Ugur Sahin, Co-Founder and Chief Executive Officer · 2026-08-04 The B7 H3 ADC is positioned as a versatile collaborator with Pumitamig, and the first combo data in lung are expected later this year. For the rest of 2026, three pivotal trial readouts are slated: gotistobart in squamous NSCLC, BNT113 in head and neck cancer, and T-PAM (the HER2 ADC) in breast cancer. These interims will be pivotal for early commercial validation. The company also confirmed the first patient dosed in the Phase III mCRPC study for the B7-H3 ADC. Ugur added a cautious but hopeful note: “We are positive. We have, of course, positive expectations for each of the trials.” — Ugur Sahin, Co-Founder and Chief Executive Officer · 2026-08-04 The market is watching this transition closely. BioNTech's PD-L1 bispecific is the centerpiece, but the CEO change and revised guidance inject uncertainty. The company is essentially trading a variable COVID dividend for a pipeline of potential blockbusters. Whether new CEO Guido Oelkers can scale the organization to execute on those readouts is the open question.

Our mission remains constant to translate science into survival.
Ugur Sahin, Co-Founder and Chief Executive Officer · 2026-08-04

That mission is now in the hands of a new leader, a leaner R&D budget, and a phalanx of late-stage trials – a fitting description of BioNTech's next chapter.